Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29121700 | 0.87 | HCAR3 (0.36) | NLRP3DNM1SMN1; SMN2MAPTP2RX3 | |
| SCHEMBL29122251 | 0.87 | HCAR3 (0.36) | NLRP3DNM1SMN1; SMN2MAPTP2RX3 | |
| SCHEMBL29121702 | 0.87 | HCAR3 (0.36) | NLRP3DNM1SMN1; SMN2MAPTP2RX3 | |
| SCHEMBL23467048 | 0.86 | NLRP3 (0.40) | NLRP3DNM1SMN1; SMN2MAPTELANE | |
| SCHEMBL23229140 | 0.85 | NLRP3 (0.38) | NLRP3DNM1SMN1; SMN2MAPTELANE | |
| SCHEMBL17419177 | 0.80 | MAPK8 (0.42) | DNM1SMN1; SMN2MAPTP2RX3ELANE | |
| SCHEMBL29121913 | 0.79 | DNM1 (0.39) | DNM1SMN1; SMN2MAPTP2RX3ELANE | |
| SCHEMBL23219249 | 0.78 | KDM4E (0.39) | NLRP3DNM1SMN1; SMN2MAPTLMNA | |
| SCHEMBL15970798 | 0.78 | MAPK8 (0.40) | NLRP3DNM1SMN1; SMN2MAPTELANE | |
| SCHEMBL6112453 | 0.78 | POLB (0.47) | SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| CN-117120419-A | KLK5 bicyclic heteroaromatic inhibitors | 拜奥克里斯特制药公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | NLRP3 1428/4885DNM1 4006/4885SMN1; SMN2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.